Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Type2 Diabetes
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
In this randomized, double-blind, parallel, placebo-controlled trial we compare the effects of semaglutide 1.34 mg/ml vs. normal dieting by randomizing the patients with both T2DM and overweight/obesity (BMI ?27) (n=50, aged ?18 to < 65 years) to two groups: both groups participate in a similar life...
In this randomized, double-blind, parallel, placebo-controlled trial we compare the effects of semaglutide 1.34 mg/ml vs. normal dieting by randomizing the patients with both T2DM and overweight/obesity (BMI ?27) (n=50, aged ?18 to < 65 years) to two groups: both groups participate in a similar lifestyle treatment to induce weight loss, but one group gets an add-on of semaglutide 1.34mg/ml while the other is treated with placebo. Additionally, a reference group of healthy normal weight non-diabetic individuals (BMI ? 25 kg/m2, n=25, aged ?18 to < 65 years) are included as controls at the initiation of the study.
Tracking Information
- NCT #
- NCT04854083
- Collaborators
- University of Helsinki
- Turku University Hospital
- Investigators
- Principal Investigator: Kirsi Pietiläinen, MD PhD Helsinki University Central Hospital
Get Well Soon